 Connection
Pamela Zeitlin to Cystic Fibrosis
This is a "connection" page, showing publications Pamela Zeitlin has written about Cystic Fibrosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
5.609 |
|
|
|
-
Shaughnessy CA, Yadav S, Bratcher PE, Zeitlin PL. Receptor-mediated activation of CFTR via prostaglandin signaling pathways in the airway. Am J Physiol Lung Cell Mol Physiol. 2022 03 01; 322(3):L305-L314.
Score: 0.346
-
Bratcher PE, Zeitlin PL. Expanding CFTR Modulator Testing to Carriers of CFTR Variants. Ann Am Thorac Soc. 2021 11; 18(11):1776-1779.
Score: 0.342
-
Bratcher PE, Yadav S, Shaughnessy CA, Thornell IM, Zeitlin PL. Effect of apical chloride concentration on the measurement of responses to CFTR modulation in airway epithelia cultured from nasal brushings. Physiol Rep. 2020 10; 8(19):e14603.
Score: 0.317
-
Zeitlin PL, Diener-West M, Callahan KA, Lee S, Talbot CC, Pollard B, Boyle MP, Lechtzin N. Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding. Ann Am Thorac Soc. 2017 Feb; 14(2):220-229.
Score: 0.246
-
Lee S, Henderson MJ, Schiffhauer E, Despanie J, Henry K, Kang PW, Walker D, McClure ML, Wilson L, Sorscher EJ, Zeitlin PL. Interference with ubiquitination in CFTR modifies stability of core glycosylated and cell surface pools. Mol Cell Biol. 2014 Jul; 34(14):2554-65.
Score: 0.205
-
Jozwik CE, Pollard HB, Srivastava M, Eidelman O, Fan Q, Darling TN, Zeitlin PL. Antibody microarrays: analysis of cystic fibrosis. Methods Mol Biol. 2012; 823:179-200.
Score: 0.173
-
Zeitlin PL. Pseudomonas aeruginosa: can studies in engineered cells tell us why is it such a problem in people with cystic fibrosis? Focus on "Cystic fibrosis transmembrane conductance regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosa". Am J Physiol Cell Physiol. 2009 Aug; 297(2):C235-7.
Score: 0.145
-
Paranjape SM, Zeitlin PL. Atypical cystic fibrosis and CFTR-related diseases. Clin Rev Allergy Immunol. 2008 Dec; 35(3):116-23.
Score: 0.140
-
Zeitlin PL. Cystic fibrosis and estrogens: a perfect storm. J Clin Invest. 2008 Dec; 118(12):3841-4.
Score: 0.139
-
MacDonald KD, McKenzie KR, Henderson MJ, Hawkins CE, Vij N, Zeitlin PL. Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice. Am J Physiol Lung Cell Mol Physiol. 2008 Nov; 295(5):L933-40.
Score: 0.138
-
Vij N, Amoako MO, Mazur S, Zeitlin PL. CHOP transcription factor mediates IL-8 signaling in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol. 2008 Feb; 38(2):176-84.
Score: 0.128
-
Zeitlin PL. Emerging drug treatments for cystic fibrosis. Expert Opin Emerg Drugs. 2007 May; 12(2):329-36.
Score: 0.125
-
Lee CKK, Boyle MP, Diener-West M, Brass-Ernst L, Noschese M, Zeitlin PL. Levofloxacin pharmacokinetics in adult cystic fibrosis. Chest. 2007 Mar; 131(3):796-802.
Score: 0.124
-
MacDonald KD, McKenzie KR, Zeitlin PL. Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation. Paediatr Drugs. 2007; 9(1):1-10.
Score: 0.122
-
Zeitlin PL. Is it go or NO go for S-nitrosylation modification-based therapies of cystic fibrosis transmembrane regulator trafficking? Mol Pharmacol. 2006 Oct; 70(4):1155-8.
Score: 0.119
-
Vij N, Fang S, Zeitlin PL. Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J Biol Chem. 2006 Jun 23; 281(25):17369-17378.
Score: 0.116
-
Singh OV, Vij N, Mogayzel PJ, Jozwik C, Pollard HB, Zeitlin PL. Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells. J Proteome Res. 2006 Mar; 5(3):562-71.
Score: 0.115
-
Laube BL, Geller DE, Lin TC, Dalby RN, Diener-West M, Zeitlin PL. Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis. Respir Care. 2005 Nov; 50(11):1438-44.
Score: 0.113
-
Zeitlin P. Can curcumin cure cystic fibrosis? N Engl J Med. 2004 Aug 05; 351(6):606-8.
Score: 0.103
-
Lim M, McKenzie K, Floyd AD, Kwon E, Zeitlin PL. Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol. 2004 Sep; 31(3):351-7.
Score: 0.102
-
Zeitlin PL, Boyle MP, Guggino WB, Molina L. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest. 2004 Jan; 125(1):143-9.
Score: 0.099
-
Zeitlin PL. Emerging drug treatments for cystic fibrosis. Expert Opin Emerg Drugs. 2003 Nov; 8(2):523-35.
Score: 0.098
-
Powell K, Zeitlin PL. Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting. Adv Drug Deliv Rev. 2002 Dec 05; 54(11):1395-408.
Score: 0.092
-
Kotas ME, Moore CM, Gurrola JG, Pletcher SD, Goldberg AN, Alvarez R, Yamato S, Bratcher PE, Shaughnessy CA, Zeitlin PL, Zhang IH, Li Y, Montgomery MT, Lee K, Cope EK, Locksley RM, Seibold MA, Gordon ED. IL-13-programmed airway tuft cells produce PGE2, which promotes CFTR-dependent mucociliary function. JCI Insight. 2022 07 08; 7(13).
Score: 0.090
-
Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, Brass-Ernst L. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther. 2002 Jul; 6(1):119-26.
Score: 0.089
-
Shaughnessy CA, Zeitlin PL, Bratcher PE. Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro. J Cyst Fibros. 2022 07; 21(4):637-643.
Score: 0.087
-
Lee AJ, Huffmyer JL, Thiele EL, Zeitlin PL, Chatterjee D. The Changing Face of Cystic Fibrosis: An Update for Anesthesiologists. Anesth Analg. 2022 06 01; 134(6):1245-1259.
Score: 0.087
-
Nick HJ, Zeitlin PL, Yadav S, Bratcher PE. Measurements of spontaneous CFTR-mediated ion transport without acute channel activation in airway epithelial cultures after modulator exposure. Sci Rep. 2021 11 19; 11(1):22616.
Score: 0.086
-
Shaughnessy CA, Zeitlin PL, Bratcher PE. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Sci Rep. 2021 10 06; 11(1):19810.
Score: 0.085
-
Laube BL, Carson KA, Evans CM, Aksit MA, Collaco JM, Richardson VL, Sharpless G, Zeitlin PL, Cutting GR, Mogayzel PJ. Characterizing mucociliary clearance in young children with cystic fibrosis. Pediatr Res. 2022 02; 91(3):612-620.
Score: 0.082
-
Laube BL, Carson KA, Evans CM, Richardson VL, Sharpless G, Zeitlin PL, Mogayzel PJ. Changes in mucociliary clearance over time in children with cystic fibrosis. Pediatr Pulmonol. 2020 09; 55(9):2307-2314.
Score: 0.077
-
Dalesio NM, Aksit MA, Ahn K, Raraigh KS, Collaco JM, McGrath-Morrow S, Zeitlin PL, An SS, Cutting GR. Cystic fibrosis transmembrane conductance regulator function, not TAS2R38 gene haplotypes, predict sinus surgery in children and young adults with cystic fibrosis. Int Forum Allergy Rhinol. 2020 06; 10(6):748-754.
Score: 0.077
-
Donaldson SH, Laube BL, Corcoran TE, Bhambhvani P, Zeman K, Ceppe A, Zeitlin PL, Mogayzel PJ, Boyle M, Locke LW, Myerburg MM, Pilewski JM, Flanagan B, Rowe SM, Bennett WD. Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR. JCI Insight. 2018 12 20; 3(24).
Score: 0.070
-
Zemanick ET, Wagner BD, Robertson CE, Ahrens RC, Chmiel JF, Clancy JP, Gibson RL, Harris WT, Kurland G, Laguna TA, McColley SA, McCoy K, Retsch-Bogart G, Sobush KT, Zeitlin PL, Stevens MJ, Accurso FJ, Sagel SD, Harris JK. Airway microbiota across age and disease spectrum in cystic fibrosis. Eur Respir J. 2017 11; 50(5).
Score: 0.065
-
Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, Taylor-Cousar JL. Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017 May; 16(3):371-379.
Score: 0.062
-
Shen Y, Liu J, Zhong L, Mogayzel PJ, Zeitlin PL, Sosnay PR, Zhao S. Clinical Phenotypes and Genotypic Spectrum of Cystic Fibrosis in Chinese Children. J Pediatr. 2016 Apr; 171:269-76.e1.
Score: 0.057
-
Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2014 Jul; 2(7):539-47.
Score: 0.051
-
Schiffhauer ES, Vij N, Kovbasnjuk O, Kang PW, Walker D, Lee S, Zeitlin PL. Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelia. Am J Physiol Lung Cell Mol Physiol. 2013 Mar 01; 304(5):L324-31.
Score: 0.046
-
Suk JS, Boylan NJ, Trehan K, Tang BC, Schneider CS, Lin JM, Boyle MP, Zeitlin PL, Lai SK, Cooper MJ, Hanes J. N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles. Mol Ther. 2011 Nov; 19(11):1981-9.
Score: 0.042
-
Kovell LC, Wang J, Ishman SL, Zeitlin PL, Boss EF. Cystic fibrosis and sinusitis in children: outcomes and socioeconomic status. Otolaryngol Head Neck Surg. 2011 Jul; 145(1):146-53.
Score: 0.042
-
Henderson MJ, Singh OV, Zeitlin PL. Applications of proteomic technologies for understanding the premature proteolysis of CFTR. Expert Rev Proteomics. 2010 Aug; 7(4):473-86.
Score: 0.039
-
Henderson MJ, Vij N, Zeitlin PL. Ubiquitin C-terminal hydrolase-L1 protects cystic fibrosis transmembrane conductance regulator from early stages of proteasomal degradation. J Biol Chem. 2010 Apr 09; 285(15):11314-25.
Score: 0.038
-
Green DM, Leonard AR, Paranjape SM, Rosenstein BJ, Zeitlin PL, Mogayzel PJ. Transient effectiveness of vitamin D2 therapy in pediatric cystic fibrosis patients. J Cyst Fibros. 2010 Mar; 9(2):143-9.
Score: 0.038
-
Leonard A, Davis E, Rosenstein BJ, Zeitlin PL, Paranjape SM, Peeler D, Maynard C, Mogayzel PJ. Description of a standardized nutrition classification plan and its relation to nutritional outcomes in children with cystic fibrosis. J Pediatr Psychol. 2010 Jan-Feb; 35(1):6-13.
Score: 0.036
-
Suk JS, Lai SK, Wang YY, Ensign LM, Zeitlin PL, Boyle MP, Hanes J. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials. 2009 May; 30(13):2591-7.
Score: 0.035
-
Green D, Carson K, Leonard A, Davis JE, Rosenstein B, Zeitlin P, Mogayzel P. Current treatment recommendations for correcting vitamin D deficiency in pediatric patients with cystic fibrosis are inadequate. J Pediatr. 2008 Oct; 153(4):554-9.
Score: 0.034
-
Murray KL, Lee CK, Mogayzel PJ, Zeitlin PL, Rosenstein BJ. Dietary supplement use in pediatric patients with cystic fibrosis. Am J Health Syst Pharm. 2008 Mar 15; 65(6):562-5.
Score: 0.033
-
Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Carter BJ, Martin DB, Heald AE. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther. 2007 Aug; 18(8):726-32.
Score: 0.032
-
Hsu SC, Groman JD, Merlo CA, Naughton K, Zeitlin PL, Germain-Lee EL, Boyle MP, Cutting GR. Patients with mutations in Gsalpha have reduced activation of a downstream target in epithelial tissues due to haploinsufficiency. J Clin Endocrinol Metab. 2007 Oct; 92(10):3941-8.
Score: 0.032
-
Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol. 2007 Jul; 42(7):610-23.
Score: 0.032
-
Buranawuti K, Boyle MP, Cheng S, Steiner LL, McDougal K, Fallin MD, Merlo C, Zeitlin PL, Rosenstein BJ, Mogayzel PJ, Wang X, Cutting GR. Variants in mannose-binding lectin and tumour necrosis factor alpha affect survival in cystic fibrosis. J Med Genet. 2007 Mar; 44(3):209-14.
Score: 0.030
-
Pollard HB, Eidelman O, Jozwik C, Huang W, Srivastava M, Ji XD, McGowan B, Norris CF, Todo T, Darling T, Mogayzel PJ, Zeitlin PL, Wright J, Guggino WB, Metcalf E, Driscoll WJ, Mueller G, Paweletz C, Jacobowitz DM. De novo biosynthetic profiling of high abundance proteins in cystic fibrosis lung epithelial cells. Mol Cell Proteomics. 2006 Sep; 5(9):1628-37.
Score: 0.030
-
Wright JM, Merlo CA, Reynolds JB, Zeitlin PL, Garcia JG, Guggino WB, Boyle MP. Respiratory epithelial gene expression in patients with mild and severe cystic fibrosis lung disease. Am J Respir Cell Mol Biol. 2006 Sep; 35(3):327-36.
Score: 0.029
-
Srivastava M, Eidelman O, Jozwik C, Paweletz C, Huang W, Zeitlin PL, Pollard HB. Serum proteomic signature for cystic fibrosis using an antibody microarray platform. Mol Genet Metab. 2006 Apr; 87(4):303-10.
Score: 0.029
-
Flotte TR, Schwiebert EM, Zeitlin PL, Carter BJ, Guggino WB. Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy. Hum Gene Ther. 2005 Aug; 16(8):921-8.
Score: 0.028
-
Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, Lavange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol. 2005 Apr; 39(4):339-48.
Score: 0.027
-
Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, Noth I, Waltz D, Zeitlin P, Ramsey B, Starko K. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol. 2005 Mar; 39(3):209-18.
Score: 0.027
-
Croteau GA, Martin DB, Camp J, Yost M, Conrad C, Zeitlin PL, Heald AE. Evaluation of exposure and health care worker response to nebulized administration of tgAAVCF to patients with cystic fibrosis. Ann Occup Hyg. 2004 Nov; 48(8):673-81.
Score: 0.026
-
Standaert TA, Boitano L, Emerson J, Milgram LJ, Konstan MW, Hunter J, Berclaz PY, Brass L, Zeitlin PL, Hammond K, Davies Z, Foy C, Noone PG, Knowles MR. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol. 2004 May; 37(5):385-92.
Score: 0.025
-
Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, Hamblett N, Heald AE. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest. 2004 Feb; 125(2):509-21.
Score: 0.025
-
Ordoñez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med. 2003 Dec 15; 168(12):1471-5.
Score: 0.024
-
Boyle MP, Diener-West M, Milgram L, Knowles M, Foy C, Zeitlin P, Standaert T. A multicenter study of the effect of solution temperature on nasal potential difference measurements. Chest. 2003 Aug; 124(2):482-9.
Score: 0.024
-
Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, Conrad CK, Brass-Ernst L, Humphries M, Sullivan K, Wetzel R, Taylor G, Carter BJ, Guggino WB. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther. 2003 Jul 20; 14(11):1079-88.
Score: 0.024
-
Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003 Mar 15; 167(6):841-9.
Score: 0.023
-
Groman JD, Meyer ME, Wilmott RW, Zeitlin PL, Cutting GR. Variant cystic fibrosis phenotypes in the absence of CFTR mutations. N Engl J Med. 2002 Aug 08; 347(6):401-7.
Score: 0.023
-
Tang BC, Dawson M, Lai SK, Wang YY, Suk JS, Yang M, Zeitlin P, Boyle MP, Fu J, Hanes J. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci U S A. 2009 Nov 17; 106(46):19268-73.
Score: 0.009
-
Liang L, MacDonald K, Schwiebert EM, Zeitlin PL, Guggino WB. Spiperone, identified through compound screening, activates calcium-dependent chloride secretion in the airway. Am J Physiol Cell Physiol. 2009 Jan; 296(1):C131-41.
Score: 0.009
-
Uwaifo O, Bamford P, Zeitlin PL, Blaisdell CJ. Acidic pH hyperpolarizes nasal potential difference. Pediatr Pulmonol. 2006 Feb; 41(2):151-7.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|